The Zebra GuideUnderstand · Manage
Library

What these compounds actually are

One page per compound: what it is, how it is thought to work, what the evidence genuinely shows, whether any regulator has approved it, and what the risks are. Where a compound is an approved medicine, that is stated. Where there is no human evidence at all, that is stated too.

How to read these pages

Most of what gets discussed in peptide circles has never been tested in a person. That does not make it useless, but it does mean the honest answer to "what dose should I take" is usually "nobody has established one". These pages say so rather than filling the gap with a number from a forum.

Tissue Repair BPC-157

The one the EDS community asks about most. Animal data on tendon and gut healing is genuinely interesting; human data barely exists.

Tissue Repair TB-500

A fragment of a protein your body already makes. Human trials exist, which is unusual here, but they were for eyes and wounds rather than joints.

Tissue Repair GHK-Cu

Strong evidence as a skin ingredient you put on. Much weaker evidence as something you inject.

Tissue Repair KLOW blend

Four compounds in one vial. Each has its own thin evidence base, and the combination has none at all.

Tissue Repair GLOW blend

KLOW without the KPV. Same situation: no studies of the combination.

Tissue Repair Wolverine blend

The two repair peptides together. Popular in injury contexts; the pairing itself is untested.

Growth Hormone Axis Ipamorelin

Made it into real human trials, then was dropped. Selective, short-acting, and genuinely studied — just not approved.

Growth Hormone Axis CJC-1295

A growth hormone releasing hormone analogue. The 'with DAC' version lasts days rather than minutes.

Growth Hormone Axis Tesamorelin

One of the few here that is an actual approved medicine — for a specific condition that is not hypermobility.

Incretin / GLP-1 PLP-1 S

The compound behind Ozempic and Wegovy. Approved, extensively studied, and with a side-effect profile that matters a lot if you have EDS.

Incretin / GLP-1 PLP-2 T

Dual GIP and GLP-1. Approved as Mounjaro and Zepbound. Same gastric emptying caution as semaglutide, and then some.

Incretin / GLP-1 PLP-3 R

Triple agonist, still in Phase 3, not approved anywhere. The Phase 2 results were striking, which is exactly why caution matters.

Metabolic MOTS-c

A peptide your mitochondria encode themselves. Interesting biology, almost entirely animal evidence.

Neuro & Sleep DSIP

Named for an effect that later research struggled to reproduce consistently.

Neuro & Sleep Semax

Approved in Russia, nowhere else. Most of the literature is in Russian and hard to appraise from outside.

Metabolic Glutathione

A real and important antioxidant. Whether injecting it does more than eating well is the open question.

Metabolic NAD+

Not a peptide. A coenzyme central to energy metabolism, sold widely on the back of ageing research.

Reproductive & Hormonal PT-141

Another genuinely approved one, for a narrow indication.

Reproductive & Hormonal Melanotan II

The one with the clearest documented harms. Worth reading the risks before anything else.

Immune Thymosin alpha-1

Approved in a number of countries, though not the US. Mainly an immune modulator.

The rest of the catalog, in brief

These have the same answer as most of the library — little or no human evidence — so they get a line each rather than a page that repeats itself.

SermorelinGHRH analogue. Was approved in the US as Geref and later withdrawn from the market for commercial reasons.
GHRP-6Older growth hormone secretagogue. Strongly stimulates appetite. Not approved.
HexarelinPotent GH secretagogue; tolerance develops quickly. Not approved.
IGF-1 LR3Long-acting IGF-1 analogue. Not approved; significant hypoglycaemia risk.
IGF-DESIGF-1 variant. Not approved. Same hypoglycaemia concern.
ACE-031Myostatin pathway inhibitor. Human trials were halted over bleeding and vascular side effects.
GDF-8Myostatin itself. Research reagent, not a therapeutic.
CagrilintideAmylin analogue, investigational, studied in combination with semaglutide.
SurvodutideGLP-1 and glucagon dual agonist. Investigational, Phase 3.
MazdutideGLP-1 and glucagon dual agonist. Investigational in the US.
AOD9604Growth hormone fragment. Failed to beat placebo for weight loss in human trials.
5-Amino-1MQNNMT inhibitor. Preclinical only.
SLU-PP-332ERR agonist, exercise-mimetic research compound. Preclinical only.
AICARAMPK activator. Research compound; prohibited in sport.
SS-31Also called elamipretide. Mitochondria-targeted; has been through human trials in rare mitochondrial disease.
EpitalonTetrapeptide with telomerase claims resting on limited Russian-language work.
PinealonShort peptide from the same Russian bioregulator tradition. Minimal independent evidence.
SelankAnxiolytic peptide registered in Russia. Not approved elsewhere.
FOXO4-DRISenolytic research peptide. Mouse data only.
ThymalinThymic extract from the Russian bioregulator literature.
LL-37Human antimicrobial peptide. Research use; pro-inflammatory effects are dose-dependent.
ARA-290Erythropoietin-derived peptide studied in small trials for sarcoidosis-related neuropathy.
VIPVasoactive intestinal peptide. Investigational.
PNC-27Anti-cancer research peptide. Cell-culture evidence only; no human trials.
KPVAlpha-MSH fragment with anti-inflammatory activity in animal colitis models.
KisspeptinRegulates GnRH release. Used as a research probe of reproductive physiology.
HCGAn approved medicine with established fertility and endocrine indications.
HMGApproved gonadotropin preparation used in fertility treatment.
Snap-8Cosmetic peptide used topically in skincare.
B12Cyanocobalamin. An established vitamin preparation, not a research peptide.